Open AccessMET Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Author(s) -
Robin Guo,
Michael Offin,
A. Rose Bran,
Jason C. Chang,
Andrew Chow,
Lukas Delasos,
Jeffrey Girshman,
Olivia Wilkins,
Caroline G. McCarthy,
Alex Makhnin,
Christina J. Falcon,
Kerry Scott,
Yuan Tian,
Fabiola Cecchi,
Todd Hembrough,
Deepu Alex,
Ronglai Shen,
Ryma Benayed,
Bob T. Li,
Charles M. Rudin,
Mark G. Kris,
Maria E. Arcila,
Natasha Rekhtman,
Paul K. Paik,
Ahmet Zehir,
Alexander Drilon
Publication year - 2021
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-2861
Subject(s) - exon , lung cancer , cancer research , biology , gene duplication , medicine , oncology , gene , genetics
MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14-altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and comprehensive proteomic analyses have not previously been performed.